Searchable abstracts of presentations at key conferences in endocrinology

ea0003p114 | Diabetes & Metabolism | BES2002

Lectin binding of serum hCG in pregnancy and type 1 diabetes

Nayar R , Dillon S , McNab G , Chapman A

Advanced glycation end products modify protein structure and function in type I diabetes. Glycoproteins may be potentially modified through other mechanisms, particularly changes to insulin-dependent oligosaccharide components. We have assessed the use of immobilised lectins, characterising the oligosaccharides of a serum glycoprotein, human chorionic gonadotrophin (hCG). We wish to test the hypothesis that glycoprotein glycosylation may be modified in type I diabetes.<p ...

ea0089c32 | Clinical – Surgery/Applied Pathology | NANETS2022

Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Ziogas, MD, MPH Ioannis A. , T. Tasoudis, MD Panagiotis , C. Borbon, MD Luis , K. Sherman, MD, FACS Scott , J. Breheny, MS, PhD Patrick , Chandrasekharan, MBBS Chandrikha , S. Dillon, MD Joseph , M. Bellizzi, MD Andrew , R. Howe, MD, FACS James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The WHO 2017 classification further subdivided G3 NENs into G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Current guidelines favor medical management in most of these patients, and the role of surgical management is not well-defined. We performed a systematic literature review and meta-analysis of surgical management vs ...

ea0089c37 | Clinical – Surgery/Applied Pathology | NANETS2022

Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

C. Borbon, MD Luis , G. Tran, MD Catherine , K. Sherman, MD Scott , Hien Ear, PhD Po , Chandrasekharan, MD Chandrikha , M. Bellizzi, MD Andrew , S. Dillon, MD Joseph , M. O'Dorisio, MD Thomas , R. Howe, MD James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is usually recommended. This study sought to evaluate outcomes of surgically treated G3 GEP-NEN patients.Methods: A single-institutional prospective NEN database was reviewed. Patients with G3 GEP-NENs based on World Health Organization (WHO) 2019 definitions included well-differentiated neur...